Nautilus Biotechnology Inc
NASDAQ:NAUT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (26.5), the stock would be worth $-10.62 (513% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -6.4 | $2.57 |
0%
|
| Industry Average | 26.5 | $-10.62 |
-513%
|
| Country Average | 13.3 | $-5.35 |
-308%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
325m USD | -6.4 | -5.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
962.6B USD | 1 651.2 | 3 990.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.9B USD | 21 | 25.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
127.8B USD | 19.9 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 36.6 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 17.4 | 15.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 29.2 | -122.9 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 23.4 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.4B USD | 45.1 | 45.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.8B USD | 10.5 | 20.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 27.2 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Nautilus Biotechnology Inc
Glance View
Nautilus Biotechnology, Inc. operates as a life sciences company. The company is headquartered in Seattle, Washington and currently employs 113 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The firm is developing a prototype of a single-molecule instrument, Proteomic Analysis System. The Company’s Proteomic Analysis Platform leverages a nanofabricated, single-molecule protein array, multi-cycle imaging, and machine learning analysis to identify and measure the proteome with sensitivity and scale.
